One Novavax vaccine candidate study demonstrated an efficacy of 44% in reducing RSV-LRTI, 35% in reducing RSV-LRTI hospitalisation and 47% in reducing severe hypoxaemia in the first 3 months of life, although these reported efficacies did not achieve significance in their primary end-point (LRTI in infants after 3 months of birth) [ 17 ].
← all excerpts
Antibody-mediated protection against respiratory syncytial virus in children.
1
—
—